Payment overview · 2025
General Payments
$1,541.79
79 reported records · 19 companies
Healthcare provider profile · identity verified
Brandy Junkin, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · TUSCALOOSA, AL · NPI 1902259443
Verified facts
What the public records show
CMS Open Payments records show Brandy Junkin, CRNP received $1,541.79 in general payments during 2025 across 79 reported records.
ABBVIE INC. accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $270.06 | 17.5% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $207.75 | 13.5% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $171.77 | 11.1% | 10 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $149.68 | 9.7% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $98.82 | 6.4% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $92.61 | 6.0% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $91.94 | 6.0% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $81.92 | 5.3% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $65.00 | 4.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.23 | 4.1% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $40.92 | 2.6% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $35.87 | 2.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.64 | 2.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.30 | 2.0% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.06 | 1.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $22.89 | 1.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.49 | 1.4% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $21.03 | 1.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.81 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,498.54 | 78 |
| Education | $43.25 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $183.58 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $171.77 | 10 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $149.68 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $149.09 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $98.82 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $92.61 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $91.94 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $81.92 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $81.92 | 5 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $65.00 | 3 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $43.25 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $40.92 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $35.87 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.64 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.64 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $33.77 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $31.30 | 2 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $30.32 | 3 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $29.72 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.47 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.47 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 19 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 118 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 166 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
118 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
166 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 166 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 141 | 76 |
| Metformin Hcl | Metformin Hcl | 135 | 58 |
| Mounjaro | Tirzepatide | 118 | 30 |
| Omeprazole | Omeprazole | 89 | 50 |
| Gabapentin | Gabapentin | 79 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 35 |
| Meloxicam | Meloxicam | 65 | 33 |
| Lisinopril | Lisinopril | 61 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 60 | 30 |
| Celecoxib | Celecoxib | 55 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 48 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 19 |
| Buspirone Hcl | Buspirone Hcl | 45 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 24 |
| Losartan Potassium | Losartan Potassium | 44 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 19 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 38 | 18 |
| Trazodone Hcl | Trazodone Hcl | 38 | 23 |
| Carvedilol | Carvedilol | 37 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 35 | 18 |
| Famotidine | Famotidine | 34 | 21 |
| Furosemide | Furosemide | 34 | 25 |
| Fluconazole | Fluconazole | 31 | 17 |
| Tramadol Hcl | Tramadol Hcl | 31 | 17 |
| Methocarbamol | Methocarbamol | 30 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 28 | 17 |
| Potassium Chloride | Potassium Chloride | 28 | 15 |
| Pregabalin | Pregabalin | 28 | 11 |
| Sertraline Hcl | Sertraline Hcl | 28 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 11 |
| Clonidine Hcl | Clonidine Hcl | 25 | 12 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | 13 |
| Alendronate Sodium | Alendronate Sodium | 23 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 23 | 18 |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | 13 |
| Eliquis | Apixaban | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 15 |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Linzess | Linaclotide | 19 | 11 |
| Mupirocin | Mupirocin | 19 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 11 |
| Allopurinol | Allopurinol | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | 12 |
| Meclizine Hcl | Meclizine Hcl | 18 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 18 | 13 |
| Azithromycin | Azithromycin | 17 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | 12 |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | 15 |
| Nystatin | Nystatin | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,541.79 · 79 records | ABBVIE INC. | ACCRUFER, AREXVY, AUSTEDO XR, Auvelity, BEXSERO, BOTOX, CAPLYTA, CREON, ENHERTU, EPKINLY, FANAPT, GEMTESA, IBSRELA, IMBRUVICA, INGREZZA, JOURNAVX, Kerendia, LINZESS, MOUNJARO, Ozempic, QULIPTA, REXULTI, Rybelsus, SHINGRIX, SUBLOCADE, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error